We’ve recently updated our valuation analysis.

UpHealth Valuation

Is UPH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for UPH?

Other financial metrics that can be useful for relative valuation.

UPH key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.1x
Enterprise Value/EBITDA35.1x
PEG Ration/a

Price to Sales Ratio vs Peers

How does UPH's PS Ratio compare to its peers?

The above table shows the PS ratio for UPH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average3.2x
CRVW CareView Communications
4.1xn/aUS$32.2m
ICAD iCAD
1.3x15.6%US$32.8m
ICCT iCoreConnect
4.6xn/aUS$37.1m
HLYK HealthLynked
2.8xn/aUS$17.2m
UPH UpHealth
0.2x2.5%US$25.4m

Price-To-Sales vs Peers: UPH is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (3.2x).


Price to Earnings Ratio vs Industry

How does UPH's PE Ratio compare vs other companies in the US Healthcare Services Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a29.3%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a29.3%
n/an/an/a
No more companies

Price-To-Sales vs Industry: UPH is good value based on its Price-To-Sales Ratio (0.2x) compared to the US Healthcare Services industry average (2.5x)


Price to Sales Ratio vs Fair Ratio

What is UPH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

UPH PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.2x
Fair PS Ratio0.4x

Price-To-Sales vs Fair Ratio: UPH is good value based on its Price-To-Sales Ratio (0.2x) compared to the estimated Fair Price-To-Sales Ratio (0.4x).


Share Price vs Fair Value

What is the Fair Price of UPH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate UPH's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate UPH's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst UPH forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$1.53
US$7.00
+357.5%
46.7%US$11.00US$3.00n/a3
May ’24US$1.87
US$7.00
+274.3%
46.7%US$11.00US$3.00n/a3
Apr ’24US$1.49
US$7.00
+369.8%
46.7%US$11.00US$3.00n/a3
Mar ’24US$2.08
US$6.50
+212.5%
53.8%US$10.00US$3.00n/a2
Feb ’24US$2.65
US$14.33
+440.9%
79.8%US$30.00US$3.00n/a3
Jan ’24US$1.63
US$16.67
+922.5%
61.6%US$30.00US$5.00n/a3
Dec ’23US$3.48
US$25.00
+617.6%
34.6%US$30.00US$10.00n/a4
Nov ’23US$5.25
US$25.00
+376.1%
34.6%US$30.00US$10.00n/a4
Oct ’23US$5.32
US$25.00
+369.9%
34.6%US$30.00US$10.00n/a4
Sep ’23US$5.67
US$25.00
+340.8%
34.6%US$30.00US$10.00n/a4
Aug ’23US$6.50
US$38.75
+495.9%
46.9%US$60.00US$10.00n/a4
Jul ’23US$5.79
US$38.75
+569.4%
46.9%US$60.00US$10.00n/a4
Jun ’23US$7.00
US$38.75
+453.6%
46.9%US$60.00US$10.00US$1.604
May ’23US$7.99
US$41.25
+416.1%
45.7%US$60.00US$10.00US$1.874
Apr ’23US$11.80
US$41.25
+249.6%
45.7%US$60.00US$10.00US$1.494
Mar ’23US$22.90
US$86.25
+276.6%
20.6%US$105.00US$60.00US$2.084
Feb ’23US$22.50
US$86.25
+283.3%
20.6%US$105.00US$60.00US$2.654
Jan ’23US$22.40
US$97.00
+333.0%
23.4%US$130.00US$60.00US$1.635
Dec ’22US$23.80
US$97.00
+307.6%
23.4%US$130.00US$60.00US$3.485
Nov ’22US$17.60
US$113.00
+542.0%
24.7%US$140.00US$60.00US$5.255
Oct ’22US$30.30
US$130.00
+329.0%
5.4%US$140.00US$120.00US$5.324
Sep ’22US$50.90
US$130.00
+155.4%
5.4%US$140.00US$120.00US$5.674
Aug ’22US$63.00
US$130.00
+106.3%
5.4%US$140.00US$120.00US$6.504
Jul ’22US$65.30
US$140.00
+114.4%
0%US$140.00US$140.00US$5.791

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies